IL-5 antibody, antigen binding fragment thereof, and medical application therefor
AssigneesJiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
InventorsHua Ying, Jinping Shi, Yifang Wang, Qiyue Hu, Hu Ge, Weikang Tao
Life of this patent
Estimating the term…
Abstract
Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.
Claims13
A method for inhibiting human IL-5 in a human subject in need thereof, wherein the human IL-5 is associated with a disease selected from the group consisting of asthma, malignant attack of asthma, eosinophilia, Churg-Strauss syndrome, atopic dermatitis, nasal polyps and eosinophilic esophagitis, the method comprising administering to the subject a therapeutically effective amount of an anti-IL-5 antibody or antigen-binding fragment thereof, wherein the anti-IL-5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
- the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NO:
- 16, 17 and 18, respectively;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NO:
- 19, 20 and 21, respectively.
A method for inhibiting human IL-5 in a human subject in need thereof, wherein the human IL-5 is associated with a disease selected from the group consisting of asthma, malignant attack of asthma, eosinophilia, Churg-Strauss syndrome, atopic dermatitis, nasal polyps and eosinophilic esophagitis, the method comprising administering to the subject a therapeutically effective amount of an anti-IL-5 antibody or antigen-binding fragment thereof, wherein the anti-IL-5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein,
- the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NO:
- 16, 17 and 18, respectively;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NO:
- 19, 20 and 21, respectively.
Dependencies are inferred from the claim text.